Search Results
Onco
Daily
Facebook
RSS
X
Youtube
Linkedin
October, 2024
October 2024
M
T
W
T
F
S
S
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
« Sep
piotr wysocki
May 1, 2024, 07:00 |
Insight
Piotr Wysocki: Cannabis and cannabinoid in adult cancer patients
Piotr Wysocki recently shared on LinkedIn: "ASCO guidelines devoted to cannabis and cannabinoid use in adult…
Apr 28, 2024, 17:10 |
Blog
Piotr Wysocki: Metronomic Chemotherapy in Cancer Treatment - Call for Papers
Piotr Wysocki recently shared on LinkedIn: "Dear Colleagues, As a Guest Editor, I invite you to…
Apr 28, 2024, 12:38 |
Insight
Piotr Wysocki: Combined treatment (TKI+ICI) does not benefit favorable-risk mRCC patients
Piotr Wysocki recently shared on LinkedIn: "For several years, combined therapy based on the administration of…
Apr 26, 2024, 20:41 |
Insight
Piotr Wysocki: CAR-T therapy seems to be associated with second primary malignant neoplasms
Piotr Wysocki recently shared on LinkedIn: "In a research letter published online in JAMA Oncology,…
Apr 26, 2024, 17:55 |
Insight
Piotr Wysocki: NECTIN4 amplification is a predictive factor for enfortumab vedotin efficacy
Piotr Wysocki recently shared on LinkedIn: "Kluemper et al. published results of a study evaluating NECTIN4…
Apr 25, 2024, 21:09 |
Insight
Piotr Wysocki: Salvage re-irradiation is a feasible option in locally recurrent prostate cancer after primary curative radiotherapy
Piotr Wysocki recently shared on LinkedIn: "Locally recurrent prostate cancer (PC) in patients who underwent primary…
Apr 25, 2024, 21:06 |
Drugs
Piotr Wysocki: Datopotamab deruxtecan – another anti-TROP2 conjugate demonstrating activity in advanced ER+/HER2- and triple-negative breast cancer patients
Piotr Wysocki recently shared on LinkedIn: "Datopotamab deruxtecan – a novel anti-TROP2 conjugate demonstrates activity…
Apr 25, 2024, 12:40 |
Drugs
Piotr Wysocki: Similar activity of topotecan and liposomal irinotecan in second-line treatment of SCLC
Piotr Wysocki, Professor of Medicine and Head of the Department of Oncology at Jagiellonian University…
Apr 22, 2024, 18:48 |
Insight
Piotr Wysocki: Single-agent immunotherapy is a wise choice as first-line treatment in elderly, advanced NSCLC patients, irrespectively of PD-L1 expression
Piotr Wysocki, Professor of Medicine and Head of the Department of Oncology at Jagiellonian University…
Apr 22, 2024, 18:37 |
Insight
Piotr Wysocki: Postpartum breast cancer in BRCA1/2-mutation carriers is associated with poor outcomes, especially in patients with BRCA1 mutations
Piotr Wysocki, Professor of Medicine and Head of the Department of Oncology at Jagiellonian University…
4
5
6
7
8
All:
112
Posts:
51 - 60
Dikembe Mutombo: In Memory of Basketball Icon Who Died at 58 Battling Brain Cancer
100 Influential Women in Oncology: Key Opinion Leaders to Follow on Social Media in 2024: Part 7
César Milstein - The Father of Modern Immunology
ESTRO: Everything You Need to Know About European Society for Radiotherapy and Oncology
Jane Fonda Breast Cancer and Non-Hodgkin Lymphoma: How She Went Against, How She Survived, and More
Special Coverage
ASCO Annual Meeting
May 30 - June 4, 2024
Yvonne Award 2024
May 31, 2024
OncoThon 2024, Online
Feb. 15, 2024
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Facebook
RSS Feed
X
Linkedin
Youtube